Related Experiment Video
Updated: Jun 12, 2026
Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer
Rafael Rosell1, Teresa Moran, Santiago Viteri
1Hospital Germans Trias i Pujol, Catalan Institute of Oncology, Medical Oncology Service, Ctra Canyet, s/n 08916 Badalona, Barcelona, Spain. rrosell@ico.scs.es
Importance Of The Field:
Non-small-cell lung cancer (NSCLC) is a disseminated disease in 50% of cases, with a gloomy prognosis and median survivals of < 1 year.
Areas Covered In This Review:
Based on substantial advances, cancer biology insights and novel biotechnology tools, customized treatment provides hints that cisplatin-based treatment can be optimized in favorable subgroups of patients according to gene expression DNA repair profiles. In 2004, it was discovered that 10-15% of NSCLC can harbor a new class of EGFR mutation conferring specific sensitivity to EGFR tyrosine kinase inhibitors.
What The Reader Will Gain:
The homologous recombination pathway provides information for customizing cisplatin-based chemotherapy. BRCA1 plays a central role in this pathway that can be used in tailoring chemotherapy. Patient subgroups can obtain significant increases in progression-free survival. For EGFR lung-addicted cancers, treatment with EGFR tyrosine kinase inhibitors like erlotinib provide impressive improvement in progression-free survival--up to 14 months with significant enhanced survival.
Take Home Message:
Customized chemotherapy based on BRCA1 models can contribute to demonstrating this approach's clinical relevance, and the implementation of EGFR mutation assessment is warranted to identify EGFR-addicted lung cancers with a different prognosis that could benefit from a specifically targeted therapy approach.
Insights
Optimizing chemotherapy for non-small-cell lung cancer (NSCLC) involves tailoring treatments based on DNA repair profiles like BRCA1 and identifying EGFR mutations for targeted therapies, improving patient survival.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Non-small-cell lung cancer (NSCLC) frequently presents as disseminated disease with poor prognosis.
- Current median survival for NSCLC is less than one year.
Purpose of the Study:
- To review advances in customizing cancer treatment for NSCLC.
- To highlight the role of DNA repair profiles and EGFR mutations in treatment optimization.
Main Methods:
- Analysis of gene expression and DNA repair profiles for optimizing cisplatin-based chemotherapy.
- Identification of EGFR mutations conferring sensitivity to tyrosine kinase inhibitors.
Main Results:
- BRCA1's role in homologous recombination pathway informs cisplatin-based chemotherapy customization.
- Targeted therapy with EGFR inhibitors shows significant improvement in progression-free survival (up to 14 months) for EGFR-mutated NSCLC.
Conclusions:
- BRCA1-based models demonstrate clinical relevance for customized chemotherapy in NSCLC.
- EGFR mutation assessment is crucial for identifying patients who benefit from targeted therapy.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...